Home  |  Contact

UniProtKB/Swiss-Prot P38398: Variant p.Gln1200His

Breast cancer type 1 susceptibility protein
Gene: BRCA1
Variant information

Variant position:  1200
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glutamine (Q) to Histidine (H) at position 1200 (Q1200H, p.Gln1200His).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and polar.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In BC and BROVCA1.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  1200
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1863
The length of the canonical sequence.

Location on the sequence:   SVQKGELSRSPSPFTHTHLA  Q GYRRGAKKLESSEENLSSED
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SVQKGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSED

Gorilla                       NVQRGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSED

                              SVQSGEFSRSPSPSDHTRLAQGYQRGTKKLESSEENMSSEE

Rhesus macaque                SIQRGELSRSPSPFTHTHLAQGYQKEAKKLESSEENLSSED

Chimpanzee                    SVQRGELSRSPSPFTHTHLAQGYRRGAKKLESSEENLSSED

Mouse                         SILRRESSRSPSPVTHASKSQSLHRASRKLESSEESDSTED

Rat                           SVLRRESSRSPSPVTHASKSRSLHRGSRKLEFSEESDSTED

Bovine                        SVQKGEFRGSPGPFTHTHLAQGHQRGAGKLE-SEETVSSED

Caenorhabditis elegans        S---ESLETPPEPI--------------------QKLAQKP

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1863 Breast cancer type 1 susceptibility protein
Region 1181 – 1216 Disordered
Modified residue 1189 – 1189 Phosphoserine
Modified residue 1191 – 1191 Phosphoserine
Modified residue 1211 – 1211 Phosphoserine
Modified residue 1217 – 1217 Phosphoserine
Modified residue 1218 – 1218 Phosphoserine
Alternative sequence 64 – 1863 Missing. In isoform 2.
Alternative sequence 224 – 1365 Missing. In isoform 5.
Alternative sequence 264 – 1366 Missing. In isoform 3 and isoform 6.


Literature citations

Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
Valarmathi M.T.; Sawhney M.; Deo S.S.V.; Shukla N.K.; Das S.N.;
Hum. Mutat. 23:205-205(2004)
Cited for: VARIANTS BC/BROVCA1 LYS-10; LYS-23; ILE-1187; HIS-1200 AND TYR-1217; VARIANTS BC ILE-1204 AND ASN-1207; VARIANTS BROVCA1 LEU-1226 AND GLY-1243; VARIANT ARG-1183;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.